Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) Director Nicholas Galakatos sold 1,369 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $23.36, for a total transaction of $31,979.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at 25.01 on Friday. Portola Pharmaceuticals has a 52 week low of $18.25 and a 52 week high of $30.95. The stock has a 50-day moving average of $22.64 and a 200-day moving average of $24.91. The company’s market cap is $1.028 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings data on Monday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter last year, the company posted ($12.94) earnings per share. Portola Pharmaceuticals’s revenue was down 23.8% compared to the same quarter last year. On average, analysts predict that Portola Pharmaceuticals will post $-3.44 earnings per share for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.